Chour, William
Choi, Jongchan
Xie, Jingyi http://orcid.org/0000-0002-8959-4268
Chaffee, Mary E.
Schmitt, Thomas M.
Finton, Kathryn
DeLucia, Diana C. http://orcid.org/0000-0002-1165-6799
Xu, Alexander M. http://orcid.org/0000-0003-4877-4358
Su, Yapeng
Chen, Daniel G. http://orcid.org/0000-0001-6660-6257
Zhang, Rongyu
Yuan, Dan
Hong, Sunga http://orcid.org/0000-0003-4412-2811
Ng, Alphonsus H. C.
Butler, Jonah Z.
Edmark, Rick A.
Jones, Lesley C.
Murray, Kim M.
Peng, Songming
Li, Guideng
Strong, Roland K.
Lee, John K. http://orcid.org/0000-0002-6570-2180
Goldman, Jason D. http://orcid.org/0000-0002-3825-6832
Greenberg, Philip D. http://orcid.org/0000-0003-3812-647X
Heath, James R. http://orcid.org/0000-0001-5356-4385
Funding for this research was provided by:
U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (HHSO10201600031C)
Article History
Received: 8 November 2022
Accepted: 1 May 2023
First Online: 16 May 2023
Competing interests
: J.R.H. is a founder and board member of Isoplexis and PACT Pharma. P.D.G. is on the scientific advisory board of Celsius, Earli, Elpiscience, Immunoscape, Rapt, Metagenomi, and Nextech, was a scientific founder of Juno Therapeutics, and receives research support from Lonza. J.D.G. declared contracted research with Gilead, Lilly, and Regeneron and served on an advisory board for Gilead. The remaining authors declare no competing interests.